EGFR Targeted Inhibition Resistance: Compensatory Activation of ERBB Family Members in Glioblastoma Cancer Stem-Like Cells Promotes Proliferation
Gursel, Demirkan B.; Schlaff, Cody D.; Boockvar, John A.
Receptor tyrosine kinase (RTK) signaling is found to be aberrant in approximately 88 percent of glioblastoma multiforme (GBMs).1 Most notably, the epidermal growth factor receptor (EGFR) is amplified or mutated in approximately half of all these cases, with a majority of these cases harboring the EGFRvIII mutation, an in-frame deletion of exons 2 to 7.2 Consequently, this deletion gives rise to a truncated receptor that retains its signal peptide, transmembrane and intracellular kinase and autophosphorylation domains, making it constitutively active and ligand independent.3 Furthermore, the constitutively active mutant has been shown to confer GBMs hallmark with increased and aggressive proliferation, survival and invasive phenotype, thus is associated with tumorigenesis.
The putative cancer stem cell (CSC), a small subset of the tumor bulk, with the capacity to self-renew has been postulated by the CSC hypothesis to be the driver behind tumor propagation and recurrence.4 Isolation and characterization of this population through the marker CD133 (Prominin-1) has shown that they are highly effective in creating neoplasms in immunodeficient mice, with as little as 102 to 103 cells necessary for successful xenographs, while those injections absent of CSCs rarely develop a neoplasm.5 Moreover, CSCs have shown the ability to be resistant to common anticancer treatments such as radiation therapy6,7 and chemotherapy.8,9 With various EGFR targeted agents (eg erlotinib, lapatinib, and cetuximab) currently in clinical trial only producing modest improvements in a small portion of the patient population, Clark et al recently reported that resistance to these targeted therapies are mediated by the activation of ERBB family members, ERBB2/HER2/neu and ERBB3/HER3.10
Four independently established GBM CSC lines harvested from primary tissue, all of which demonstrated the classical CSC properties (self-renewal, neurosphere and colony formation, multilineage potency and xenograft tumor formation) were analyzed for expression of EGFR. When exogenous mitogenic factors were removed, both CSCs and NSCs had significantly reduced proliferation, yet, in long-term culture all 4 GBM CSC lines continued to proliferate as neurospheres, albeit at a reduced observed rate and were capable of maintaining their stem-cell like properties. Clark et al, then went on to analyze the downstream signaling of these cells with and without exogenous mitogenic factors and determined, unsurprisingly, that AKT and ERK1/2 (MAPK) activation remained relatively constant with and without exogenous EGF. However they also observed upregulation and activation of ERBB2/3 after removal of exogenous EGF. Importantly, Clark and colleagues went on to observe that treating CSCs with lapatinib, which block activation of both EGFR and ERBB2, was significantly more effective at inhibiting proliferation compared to cetuximab (blocks EGFR alone) and other monospecific EGFR inhibitors (antibodies and TKIs.) Based on these results, Clark et al, concluded that GBM therapeutic resistance to anti-EGFR targeted therapies may in part be responsible for the compensatory activation of EGFR-related family members (ERBB2/3) by enabling CSC proliferation.
In glioma the mechanisms that drive therapeutic resistance and progression are largely a mystery and are the factors that make this disease so deadly and aggressive, however Clark et al offer some possible explanations for this. Firstly, autocrine or paracrine stimulation of EGFR through ligands such as EGF and amphiregulin may also confer the survival and proliferative cues to CSCs independent of exogenous EGF.11 However, it appears that the auto- or paracrine stimulation is only partially responsible as explained by the more significant reduction in proliferation after lapatinib treatment compared to cetuximab treatment. Secondly, many reports have shown that neuregulin ligands may be potential activators of ERBB-dependent cancers.12,13 Neuregulin ligands activate ERBB3 or 4, which subsequently dimerize with other family members while simultaneously activating their own downstream signaling.14 And thirdly the possibility of “off-target” effects of lapatinib; the nonspecific activity of lapatinib has been reported to include inhibition of glutathione S-transferase P1 (GSTP1), the nuclear translocation of EGFR and ERBB2 and the sterol regulatory element-binding protein-1 (SREBP-1).10 These “off-target” effects may all play a role in reducing proliferation, and the role of neuregulin, ERBB2 and ERBB3 in signaling progression and resistance are still largely unknown and need to be clarified to further understand the mechanism of GBM resistance and progression, in order to develop efficacious treatment modalities.
In addition to providing new insights on the resistance mechanism of GBM CSCs. Clark et al's results provide explanation for previously confounding reports illustrating the importance and critical need of aberrant EGFR activation for the survival and propagation of GBM.5,15 Furthermore, Clark et al's results help to explain why we see minimal improvement in clinical trials that use targeted EGFR therapies. ERBB family members have been shown in various cancers to play an important role, particularly in breast cancer.16 As Clark et al showed multitargeted therapy with lapatinib provided significant reduction in proliferation of CSCs with and without exogenous mitogenic factors. This fact combined with the observation that only GBM CSCs proliferated while the normal NSCs did not survive in the absence of EGFR signaling implicates the compensatory ERBB2/3 signaling as a tumorigenic mechanism, ergo it may be worthwhile to explore multi-EGFR receptor family inhibition treatment modalities as a strategy against GBM.
1. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–1068.
2. Schulte A, Gunther HS, Martens T, et al.. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration. Clin Cancer Res. 2012;18(7):1901–1913.
3. Del Vecchio CA, Giacomini CP, Vogel H, et al.. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms [published online ahead of print]. Oncogene. 2012. doi: 10.1038/onc.2012.280.
4. Stopschinski BE, Beier CP, Beier D. Glioblastoma cancer stem cells—From concept to clinical application [published online ahead of print]. Cancer Lett. 2012.
5. Kelly JJ, Stechishin O, Chojnacki A, et al.. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells. 2009;27(8):1722–1733.
6. Bao S, Wu Q, McLendon RE, et al.. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–760.
7. Jamal M, Rath BH, Tsang PS, Camphausen K, Tofilon PJ. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia. 2012;14(2):150–158.
8. Kang MK, Kang SK. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev. 2007;16(5):837–847.
9. Liu G, Yuan X, Zeng Z, et al.. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.
10. Clark PA, Iida M, Treisman DM, et al.. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia. 2012;14(5):420–428.
11. Higginbotham JN, Demory Beckler M, Gephart JD, et al.. Amphiregulin exosomes increase cancer cell invasion. Curr Biol. 2011;21(9):779–786.
12. De Boeck A, Pauwels P, Hensen K, et al.. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling [published online ahead of print]. Gut. 2012.
13. Wilson TR, Lee DY, Berry L, Shames DS, Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell. 2011;20(2):158–172.
14. Montero JC, Rodriguez-Barrueco R, Ocana A, Diaz-Rodriguez E, Esparis-Ogando A, Pandiella A. Neuregulins and cancer. Clin Cancer Res. 2008;14(11):3237–3241.
15. Soeda A, Inagaki A, Oka N, et al.. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J Biol Chem. 2008;283(16):10958–10966.
16. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012;12(8):553–563.
Copyright © by the Congress of Neurological Surgeons